Initial testing of dasatinib by the pediatric preclinical testing program
Authors:
- E. Anders KolbEKE. Anders Kolb
- Richard GorlickRGRichard Gorlick
- Christopher L. MortonCMChristopher L. Morton
- Richard B. LockRLRichard B. Lock
- Mayamin TajbakhshMTMayamin Tajbakhsh
- C. Patrick ReynoldsCRC. Patrick Reynolds
- 3 October 2007
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 50 (6) , 1198-1206
Abstract
Background: Dasatinib, a dual inhibitor of the src and abl tyrosine kinases, was recently approved by the Federal Drug Administration for the treatment of imatinib mesylate‐resistant chronic myeloid leukemia.Procedures: Dasatinib was tested against the Pediatric Preclinical Testing Program (PPTP) in vitro panel at concentrations ranging from 0.1 nM to 1.0 µM and was tested in vivo at a dose of 50 mg/kg administered orally twice daily 5 days per week for 4 weeks for the solid tumor xenografts and once daily for the acute lymphoblastic leukemia (ALL) xenografts.Results: Dasatinib was selectively active against the cell lines of the PPTP in vitro panel, reaching an IC50 in 6 of the 22 lines. The most sensitive were the AML line Kasumi‐1, which has a gain‐of‐function c‐Kit mutation (Asn822Lys), and the rhabdoid tumor line CHLA‐266 (IC50 approximately 10 nM for each). In the in vivo panel, dasatinib induced significant differences in EFS distribution in 8 of 32 (25%) solid tumor models and 3 of 7 ALL models. Using the time to event activity measure, dasatinib had intermediate activity against 1 of 27 (4%) evaluable solid tumor xenografts and 3 of 7 ALL xenografts. One xenograft in the ALL panel, a Philadelphia chromosome positive (Ph+) ALL xenograft, demonstrated a complete response.Conclusions: Dasatinib was active at low nanomolar concentrations against a small subset of the PPTP's in vitro panel. Dasatinib had limited in vivo activity against the PPTP solid tumor xenografts, but was highly active against a Ph+ ALL xenograft and also had anti‐leukemia activity against two other xenografts. Pediatr Blood Cancer 2008;50:1198–1206.Keywords
This publication has 37 references indexed in Scilit:
- Dasatinib Inhibits Migration and Invasion in Diverse Human Sarcoma Cell Lines and Induces Apoptosis in Bone Sarcoma Cells Dependent on Src Kinase for SurvivalCancer Research, 2007
- Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitroBreast Cancer Research and Treatment, 2007
- Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phaseBlood, 2007
- PI3-K/Akt-mediated anoikis resistance of human osteosarcoma cells requires Src activationEuropean Journal of Cancer, 2006
- Lyn Kinase Activity Is the Predominant Cellular Src Kinase Activity in Glioblastoma Tumor CellsCancer Research, 2005
- Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistanceProceedings of the National Academy of Sciences, 2005
- Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical AssaysJournal of Medicinal Chemistry, 2004
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- Src kinase contributes to the metastatic spread of carcinoma cellsOncogene, 2002
- CELLULAR FUNCTIONS REGULATED BY SRC FAMILY KINASESAnnual Review of Cell and Developmental Biology, 1997